Page 1680 - Clinical Small Animal Internal Medicine

1618 Index

male reproductive system tumors (cont’d) large intestine 500, 501 history and clinical signs
VetBooks.ir penis, prepuce, and scrotal meningoencephalitis and prognosis 1323–1324
history and clinical signs
1321–1322, 1323
liver disease 684–686
1311–1314
meningomyelitis 798–799
signalment 1321, 1323
tumors 1313–1314 metabolic bone diseases treatment 1322–1324
prognosis 1312–1315 1522, 1527 manometry 565, 566
prostate tumors 1312–1313 motility disorders 571 margination changes 663
signalment 1311–1314 myelopathy 820–821 mass effects 514–515, 514
testicular tumors 1311–1312 neurologic assessment 737 mass lesions
transmissible venereal oral cavity and salivary glands approach to the cancer
tumor 1314–1315 534, 538–541, 540, 545 patient 1199
treatment 1312–1315 pain and pain management 1203 endoscopy 519, 525
malignancies and neoplasia palliative care 1204 gastritis and gastric
activating invasion and palliative radiation therapy ulceration 548–549
metastasis 1210 1203–1204 vestibular disease 793
adjunctive therapies 1204 papillomaviruses 861–863 mast cell tumors (MCT) 1359–1367
advanced diagnostics 1201 patient evaluation 1200 biology of cancer and cancer
approach to the cancer pericardial disease 284 genetics 1209
patient 1199–1204 prostatic diseases 1163 canine 1359–1365, 1360,
avoiding immune radiation therapy 1202–1203 1363–1364
destruction 1208 recent treatment advances 1202 diagnosis/staging 1359–1362, 1360,
biology of cancer and cancer rectoanal diseases 609–610, 1361, 1365–1366
genetics 1205–1211 618–620, 619 epidemiology 1359, 1365
chemotherapy 1202 resisting cell death 1206–1207 esophageal and stomach
clinical features and diagnostic small intestine 491–492, 495, 496 cancers 1283, 1285
testing 1200 staging 1200 etiology/pathophysiology 1359
concepts and definitions 1199 stomach 487–489, 488 feline 1365–1366, 1363
cutaneous manifestations of systemic surgical management 1202 history and clinical signs 1359,
disease 1488–1490 sustaining proliferative 1360, 1365, 1365
deregulating cellular signaling 1209 intestinal cancers 1292
energetics 1209–1210 treatment 1201–1203 male reproductive system
diagnosis 1201 tumor promoting tumors 1313–1314
enabling replicative inflammation 1207–1208 prognosis 1365–1366
immortality 1205–1206 ureteral obstruction signalment 1359, 1365
end‐of‐life management 1204 1117–1119, 1121 statistical interpretation for
endoscopy 517, 518–519 urethral obstruction 1109–1111, practitioners 7–8
esophagus 478, 479 1115, 1117 treatment 1362–1366,
evading growth suppressors 1206 vestibular disease 791, 793 1363–1364, 1363
exocrine pancreatic see also individual types masticatory muscle myositis
insufficiency 584 malignant arrhythmias 461–462 (MMM) 812
feline immunodeficiency virus 884 malignant hyperthermia (MH) 376, mastocytosis 552–553
feline leukemia virus 878 389, 433–434 MAT see microscopic agglutination test
forebrain disorders 778–780 malignant lymphoma 686 matching controls 22
gallbladder and extrahepatic biliary malignant melanoma (MM) 539, matrix metalloproteinases (MMP)
ducts 721–722 1253–1256 heart failure 182
gastritis and gastric ulceration 548, MALT see mucosa‐associated lymphoid hemangiosarcoma 1344
550–551, 553 tissue valvular heart disease 245
genome instability and mammary cancer 1321–1325 matrix‐nucleation theory 1123
mutation 1207 canine mammary cancer MCM‐7 see minichromosome
grading 1200–1201 1321–1323 maintenance‐7
hepatobiliary disease 667–668, diagnosis/staging 1322, 1322, M‐CSF see macrophage colony‐
667–668 1323–1324, 1324 stimulating factors
history 1200 epidemiology 1321, 1323 MCT see mast cell tumors
imaging 1201 etiology/pathophysiology MDR see multidrug‐resistant
inducing angiogenesis 1208–1209 1321, 1323 MDS see myelodysplastic syndromes
initial assessment 1200 feline mammary cancer 1323–1324 MEA see mean electrical axis